Compare Ascendis Pharma A/S (ASND) vs Motorola Solutions Inc (MSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Motorola Solutions Inc — how do they compare? Ascendis Pharma A/S trades at $263 (market cap $17.74B), while Motorola Solutions Inc trades at $417.99 (market cap $70.20B). The key difference: Motorola Solutions Inc is far larger — about 4× Ascendis Pharma A/S's market cap, and Motorola Solutions Inc pays a 1.14% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | MSI | |
|---|---|---|
Market Cap | $17.74B | $70.20B |
Sector | Health | Technology |
52-Week High | $277.18 | $490.30 |
52-Week Low | $163.32 | $363.83 |
Enterprise Value | $18.11B | $78.90B |
Dividend Yield | — | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Motorola Solutions (MSI) trades at $422.88, up 1.36% with a bullish technical outlook. The stock shows strong fundamentals with Q1 2026 EPS beating estimates at $3.37 versus $3.24 expected, and a robust net income margin of 17.61%. Recent news highlights AI expansion in public safety, including the $1.5 billion acquisition of D-Fend Solutions, enhancing its competitive edge in counter-drone technology.
Outlook remains positive with a consensus price target of $512.33, indicating 21% upside. Risks include high valuation multiples like a P/E of 34.1 and increased debt from acquisitions. The company's focus on mission-critical AI and a $15.7 billion backlog supports growth, but investors should monitor integration execution and macroeconomic pressures on public spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →
